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Abbreviations
and Acronyms
bGS ¼ biopsy Gleason score
DCA ¼ decision curve analysis
DRE ¼ digital rectal examination
DWI ¼ diffusion weighted
imaging
%fPSA ¼ free PSA rate
mp-MRI ¼ multiparametric
magnetic resonance imaging
MRI ¼ magnetic resonance
imaging
PB ¼ prostate biopsy
PCa ¼ prostate cancer
PCA3 ¼ prostate cancer antigen 3
PHI ¼ Prostate Health Index
PSA ¼ prostate specific antigen
RB ¼ repeat biopsy
tPSA ¼ total PSA
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of Nuclear Medicine, San Giovanni Battista Hospital, University of Turin (RP), Turin, ItalyPurpose: In patients with a negative prostate biopsy and persistent suspicion
of prostate cancer, additional analyses such as the PCA3 score, PHI and multi-
parametric magnetic resonance imaging have been proposed to reduce the
number of unnecessary repeat biopsies. In this study we evaluate the diagnostic
accuracy of PCA3, PHI, multiparametric magnetic resonance imaging and
various combinations of these tests in the repeat biopsy setting.
Materials and Methods: A total of 170 patients with an initial negative prostate
biopsy and persistent suspicion of prostate cancer were enrolled in this pro-
spective study. The patients underwent measurements of the total prostate
specific antigen and free prostate specific antigen rate, along with PHI, PCA3
tests and multiparametric magnetic resonance imaging before standard repeat
biopsy that was performed by urologists blinded to the multiparametric magnetic
resonance imaging results. Multivariate logistic regression models with various
combinations of PCA3, PHI and multiparametric magnetic resonance imaging
were used to identify the predictors of prostate cancer with repeat biopsy, and
the performance of these models was compared using ROC curves, AUC analysis
and decision curve analysis.
Results: In the ROC analysis the most significant contribution was provided
by multiparametric magnetic resonance imaging (AUC 0.936), which was greater
than the contribution of the PHIþPCA3 model (p <0.001). In the multivariate
logistic regression analysis only multiparametric magnetic resonance imaging
was a significant independent predictor of prostate cancer diagnosis with
repeat biopsy (p <0.001). The results of the decision curve analysis confirmed
that the most significant improvement in the net benefit was provided by multi-
parametric magnetic resonance imaging.Accepted for publication January 10, 2014.
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PREDICTORS OF PROSTATE CANCER IN REPEAT BIOPSY SETTING 61Conclusions: Multiparametric magnetic resonance imaging provides high diagnostic accuracy in identifying
patients with prostate cancer in the repeat biopsy setting compared with PCA3 and PHI.
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prostate cancer antigen 3, humanIN cases of suspicion of prostate cancer, patients
are currently subjected to prostate biopsy, which
remains the gold standard for diagnosis.1 This
approach has its limits because in 25% to 30%
of patients with PCa the neoplastic tissue is not
included in the samples.2 Moreover in patients
with persistently increased PSA and negative PB,
the repetition of biopsies does not increase the
detection rate of PCa, which indeed decreases pro-
gressively.3 Because of the additional number of
samples there is a significant risk of complications
(infection, bleeding, acute urinary retention), anxi-
ety and social-sanitary costs.4
Recently various biomarkers have been studied to
increase the ability to predict PCa diagnosis, espe-
cially in patients with persistent suspicion of cancer
and a previous negative PB. The most promising
biomarkers are PCA3 and [-2]proPSA (p2PSA),
along with its derivative, the Prostate Health
Index.5e9 Other authors have emphasized the role
of mp-MRI in PCa diagnosis, taking advantage of
the anatomical, morphological and functional infor-
mation that it provides.10e15
To evaluate the role of new biomarkers and mp-
MRI in this setting we conducted a prospective
observational study to evaluate the diagnostic ac-
curacy of PCA3, PHI, mp-MRI and various combi-
nations of the 3 tests in patients undergoing a
standard repeat biopsy with an initial negative PB
who maintained a high suspicion of harboring PCa.MATERIALS AND METHODS
Study Design and Population
The study was performed between March 2011 and April
2013, after obtaining the approval of the ethics committee
of our institution, San Luigi Hospital in Orbassano, Italy.
Patients were prospectively included in the study if
they had a negative initial PB (12 samples) and if they
had a high suspicion of harboring PCa that warranted RB.
The inclusion criteria were persistently increased PSA
and/or positive DRE. The exclusion criteria were contra-
indications for undergoing PB (ie cannot interrupt anti-
coagulant therapy) or mp-MRI (ie claustrophobia,
presence of magnetically activated implanted devices,
metallic implants in sensitive areas) or previous prostate
treatment (ie transurethral prostate resection). Moreover
patients suspected of having anteriorly located PCa on
mp-MRI were noted by the radiologist and were excluded
from the study.Biomarkers
All patients underwent serum measurements of tPSA,
%fPSA and PHI before repeat biopsy. The PHI analyses
were performed using Hybritech Calibrated Access
assays (Beckman Coulter, Brea, California)16 after pro-
cessing with a Unicel DxI 800 Immunoassay System
analyzer (Beckman Coulter). All men underwent PCA3
testing before RB via a Progensa PCA3 assay (Gen-
Probe Inc, San Diego, California) according to the manu-
facturer’s specific instructions.
Prostate mp-MRI
All patients underwent mp-MRI with a 1.5-T scanner
(Signa Excite HD, GE Healthcare, Wauwatosa, Wiscon-
sin) using a 4-channel phase array coil combined with
an endorectal coil (Medrad, Warrendale, Pennsylvania).
The prostate and seminal vesicle anatomy was assessed
on T2-weighted images in the axial, coronal and sagittal
planes. T1 fast spin echo axial images were generated
to identify areas of intraprostatic hemorrhage and to
evaluate the pelvic nodes and bones. Functional infor-
mation was obtained by DWI and dynamic contrast
enhanced MRI. DWI was performed using axial echo
planar imaging sequences at different b-values. The
sequence parameters satisfied the recommendations from
a European consensus meeting that were published after
the beginning of this study.17 Further details on technical
parameters are reported in the supplementary Appendix
(http://jurology.com/).
All MR images were sent to a workstation and post-
processed (Functool v. 9.4.05a, GE Healthcare). A single
experienced radiologist analyzed the mp-MRI findings.
The radiologist was blinded to the pathologist biopsy re-
ports and to the biomarker results. For the purpose of this
study the radiologist had to choose between suspicion of
PCa (positive mp-MRI) or no suspicion of PCa (negative
mp-MRI). The signs considered suspicious for PCa are
reported in the supplementary Appendix.10,14,18 Overall
the mp-MRI finding was considered positive if at least 2
of the 3 MR sequences (T2-weighted, DWI and dynamic
contrast enhanced MRI) produced suspicious findings.
Prostate Biopsy and Pathology
All patients then underwent RB under transrectal ultra-
sound guidance in an ambulatory setting. Biopsies were
performed according to the Rodrı´guez-Covarrubias et al
protocol using a Hawk Ultrasound scanner 2102 EXL
with a biplanar transducer 8808 (B-K Medical, Herlev,
Denmark) and a disposable core biopsy instrument (Max-
Core) with an 18G needle and 18 mm length of sample
notch.19 When the prostate volume was less than 60 cc the
RB consisted of 18 needle biopsy cores, whereas when the
prostate volume was 60 cc or greater a 24-sample biopsy
scheme was adopted. Two dedicated urologists blinded to
62 PREDICTORS OF PROSTATE CANCER IN REPEAT BIOPSY SETTINGthe mp-MRI reports and to the biomarkers results
performed all repeat biopsies. RB complications were
recorded. Histological examination was conducted by a
dedicated uropathologist who was blinded to the bio-
markers and to the mp-MRI results according to a stan-
dardized protocol.20
Patients with a persistently high suspicion of PCa and
negative RB were followed according to our clinical prac-
tice. In particular, patients with positive mp-MRI under-
went a cognitive biopsy under transrectal ultrasound
guidance based on mp-MRI findings. The results of this
followup were not considered in this study.
Statistical Analysis
Multivariate logistic regression models were used to
identify the predictors of PCa when performing RB. The
tested models used various combinations of predictors
including base (DRE, age), base þ PCA3, base þ PHI, base
þ mp-MRI, base þ PHI þ PCA3, base þ PHI þ mp-MRI,
base þ PCA3 þ mp-MRI, and full (base, PCA3, PHI and
mp-MRI). The performance of these models was compared
using 1) ROC and AUC analysis, and 2) decision curve
analysis.21 Since %fPSA, tPSA and PHI are not indepen-
dent by construction, we included in the base model DRE
and age only.
The calibration of the fitted models was measured
using the Cessie-van Houwelingen-Copas-Hosmer statis-
tic. The AUCs were compared with DeLong’s test for 2
correlated ROC curves. The cutoffs providing the best
combination of sensitivity and specificity in the ROC
curves were determined following the Youden criterion.
Modeling and statistical analyses were performed using
the R statistical system (R Foundation for Statistical
Computing, Vienna, Austria) version 3.0.1. All tests were
2-sided and p <0.05 was considered statistically
significant.RESULTS
Population Results
A total of 187 patients were eligible according to
the inclusion criteria but 17 (9.1%) presented 1 orTable 1. Demographic and clinical characteristics
Pos RB
Total No. (%) 52 (30.6)* 11
Median age (IQR) 66 (61e70.5) 6
Median ng/ml tPSA (IQR) 7.7 (5.6e10.2)
Median %fPSA (IQR) 15.5 (12.2e20.1) 1
No. DRE (%):
Neg 44 (84.6) 11
Pos 8 (15.4)
Median ml prostate vol (IQR) 42 (39e51) 4
Median PHI (IQR) 43.9 (29.4e57.2) 3
Median PCA3 (IQR) 43 (23.5e67) 2
No. mp-MRI (%):
Neg 5 (9.6) 10
Pos 47 (90.4) 1
The chi-square test and Kruskal-Wallis test were used to compare the difference betwe
groups.
* The 52 lesions were found in 52 patients.
† p <0.05.more exclusion criteria. In particular, 4 patients
(2.1%) were excluded due to anteriorly located
prostate cancer on mp-MRI. Finally, the overall
population consisted of 170 patients. The de-
mographic and clinical characteristics of the cohort
are shown in table 1. Only 6 patients (3.5%) un-
derwent a 24-sample RB. The RB complication
rate was 5.3% (3 urinary acute retention and 6
acute prostatitis cases). The pathological details
are listed in table 2.
Multiparametric MRI missed 5 of 52 (9.6%) tu-
mors (3 bGS 6 and 2 bGS 7). PCA3 missed 22 of 52
(42.3%) tumors (10 bGS 6, 10 bGS 7 and 2 bGS 8
or greater), whereas PHI missed 30 of 52 (57.7%)
tumors (16 bGS 6, 12 bGS 7 and 2 bGS
8 or greater).
Statistical Results
The cutoffs for PCA3 and PHI in our cohort were
obtained using ROC analysis and were 32.5 (sensi-
tivity 0.659, specificity 0.750) and 48.9 (sensitivity
0.409, specificity 0.780), respectively. In the ROC
analysis, as shown in figure 1, the most significant
contribution was provided by mp-MRI. Indeed,
when added to the base model, mp-MRI had an
AUC value of 0.936, which was significantly higher
than the value of the base þ PHI þ PCA3 model
(p <0.001). Moreover when adding biomarkers to
models containing mp-MRI, there was not a signif-
icant improvement of AUC value as shown in
figure 1.
In the multivariate logistic regression analysis in
the full model only mp-MRI was a significant inde-
pendent predictor of PCa diagnosis on RB (table 3).
PCA3 was an independent predictor only in the
absence of mp-MRI, whereas PHI reached a mar-
ginal significance only in the base þ PHI model.
The specificity at a fixed sensitivity (80%, 90%
and 95%) and the sensitivity at a fixed specificityNeg RB Overall p Value
8 (69.4) 170
4.5 (59e70) 65 (60e70) 0.378
6.8 (5.1e9.6) 6.9 (5.2e9.8) 0.238
7.1 (13.1e21.2) 16.4 (12.5e21.0) 0.404
0.026†
3 (95.8) 157 (92.4)
5 (4.2) 13 (7.6)
2 (36e48) 42 (36e50) 0.698
6.3 (27.8e48.0) 37.8 (28.4e50.9) 0.016†
0 (12e36) 27 (13e49) 0.004†
<0.001†
7 (90.7) 112 (65.9)
1 (9.3) 58 (34.1)
en proportions and medians, respectively, between the positive and negative RB
Table 2. Pathological characteristics
Pos for PCa
No. pos for PCa (%) 52 (30.6)
No. bGS (%):
6 or Less 28 (16.4)
7 (3þ4) 19 (11.2)
7 (4þ3) 2 (1.2)
8 or Greater 3 (1.8)
Median pos cores (IQR) 2 (1e3)
Median % pos tissue (IQR) 3 (1.2e6.1)
Neg for PCa
No. neg for PCa (%) 118 (69.4)
No. high grade prostatic intraepithelial neoplasia (%) 10 (5.9)
No. atypical small acinar proliferation of prostate (%) 7 (4.1)
No. high grade prostatic intraepithelial neoplasia
with atypical small acinar proliferation of prostate (%)
3 (1.8)
No. atypical adenomatous hyperplasia/adenosis (%) 4 (2.4)
No. chronic inflammation (%) 39 (22.9)
No. benign/neg for malignancy (%) 55 (32.3)
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supplementary table (http://jurology.com/). The best
combination of sensitivity and specificity was dis-
played by all models containing mp-MRI. At a high
sensitivity or specificity the association of the bio-
markers with mp-MRI displayed results comparable
to those of mp-MRI alone.
The results of DCA, plotted in figure 2, confirm
that the most significant improvement in the net
benefit was provided by mp-MRI. The inclusion of
PCA3 and/or PHI to models containing mp-MRI did
not substantially improve the net benefit according
to DCA. Moreover the DCA models with mp-MRI
indicated a considerable net reduction in avoidable
biopsies compared with the biopsy all patients
strategy (fig. 3). For example, at a thresholdFigure 1. ROC analysis of various combinations of predictors in
overall population.probability of 30% (PCa prevalence of the study
30.3%), the net reduction in avoidable biopsies was
greater than 90%.DISCUSSION
The parameters traditionally used to assess the
risk of PCa, such as tPSA, %fPSA and DRE, have low
sensitivity and specificity.1 PCA3 score is considered
a better biomarker to select patients who could
benefit from a RB compared with tPSA.22 Moreover
recent studies have indicated that p2PSA and its
derivative PHI significantly improve the accuracy
in PCa detection with prostate biopsy.6,23
To date 2 studies have reported on head-to-head
comparisons between PCA3 and PHI to establish
which test has the highest accuracy in predicting
prostate cancer with RB.7,8 In the first study the
performance of the 2 biomarkers was compared in a
cohort of 246 patients undergoing initial or repeat
biopsy.7 In the RB cohort the PCA3 results were
more discriminating. In the second study Scattoni
et al evaluated the results of the 2 biomarkers in
95 patients who underwent RB.8 The authors
concluded that both examinations offer a significant
increase in diagnostic accuracy with a predominant
role for PHI.
Multiparametric MRI has also acquired a signifi-
cant role in the RB setting. Cirillo et al obtained high
positive (70%) and negative (90%) predictive values
from RB performed after mp-MRI in a cohort of 54
consecutive men with persistent suspicion of PCa.24
More recently Sciarra et al demonstrated that the
use of mp-MRI to direct biopsies can significantly
improve the sensitivity of the PCA3 score.25
Mp-MRI is also currently gaining importance in
PCa diagnosis because of the possibility that it of-
fers in performing cognitive26 or visually guided
targeted prostate biopsy.27e29 Moreover, in addition
to identifying the presence of a tumor, in positive
cases mp-MRI can localize the lesions, assess their
local extent and provide insights on their
aggressiveness.
To contribute to this field we planned this study
to compare the roles of mp-MRI, PCA3 and PHI
in the repeat biopsy setting. Because mp-MRI sup-
plies greater clinical information than serum or
urine biomarkers, comparing laboratory test results
and imaging findings might appear controversial.
Therefore, to overcome the possible limitations of
the study design, we placed biomarkers and mp-
MRI on the same level by dichotomizing the latter
so that it could only be assessed as positive or
negative for PCa, as occurred in the other tests.
Furthermore, to avoid bias the radiologist who
evaluated the mp-MRI findings, the urologists who
performed the RBs and the uropathologist who
Table 3. Multivariate logistic regression models in the overall population
Age Pos DRE PCA3 PHI Pos mp-MRI
Hosmer statistics
(8 df)
Base model:
OR (95% CI) 1.339 (0.598e3.053) 4.007 (1.264e13.918) Not applicable Not applicable Not applicable 8.559
p Value 0.479 0.020* Not applicable Not applicable Not applicable 0.380
Base þ PCA3:
OR (95% CI) 0.975 (0.411e2.324) 3.565 (1.093e12.663) 3.878 (1.273e12.947) Not applicable Not applicable 17.138
p Value 0.955 0.037* 0.020* Not applicable Not applicable 0.028
Base þ PHI:
OR (95% CI) 1.391 (0.615e3.211) 3.393 (1.041e11.992) Not applicable 3.517 (1.040e14.140) Not applicable 10.371
p Value 0.430 0.045* Not applicable 0.053 Not applicable 0.239
Base þ mp-MRI:
OR (95% CI) 2.473 (0.665e9.680) 2.962 (0.467e21.490) Not applicable Not applicable 99.521 (34e363.165) 6.134
p Value 0.179 0.275 Not applicable Not applicable 1.22e e14* 0.632
Base þ PCA3 þ mp-MRI:
OR (95% CI) 2.151 (0.536e8.954) 2.863 (0.431e21.569) 1.847 (0.257e9.901) Not applicable 94.546 (32.138e346.543) 5.846
p Value 0.280 0.301 0.503 Not applicable 3.91e e14* 0.664
Base þ PHIþ PCA3:
OR (95% CI) 1.015 (0.423e2.448) 3.096 (0.916e11.207) 3.873 (1.247e13.225) 3.438 (1.009e13.866) Not applicable 8.589
p Value 0.973 0.070 0.023* 0.057 Not applicable 0.378
Base þ PHI þ mp-MRI:
OR (95% CI) 2.448 (0.655e9.615) 3.070 (0.479e22.261) Not applicable 0.763 (0.172e4.399) 103.473 (34.489e387.452) 6.350
p Value 0.185 0.260 Not applicable 0.732 2.71e e14* 0.608
Full model:
OR (95% CI) 2.138 (0.531e8.915) 2.943 (0.441e22.143) 1.837 (0.251e9.950) 0.777 (0.175e4.492) 98.096 (32.525e396.153) 6.803
p Value 0.285 0.289 0.511 0.749 6.78e e14* 0.558
*p <0.05.
64 PREDICTORS OF PROSTATE CANCER IN REPEAT BIOPSY SETTINGreported the pathological analysis were all blinded
to the each other’s results and to the collected
biomarker results. Patients with anteriorly located
PCa were excluded from the study because they are
rarely diagnosed in a RB setting with ultrasound
guided transrectal approach. Only 4 patients wereFigure 2. DCAs of effect of various models on PCa detection.
Threshold probability to undergo biopsy is reported vs net
benefit. Broken black line represents assumption that all
patients will harbor PCa (biopsy all patients). Horizontal line
represents assumption that no patients will harbor PCa
(biopsy no patients).excluded for this reason and, thus, we believe the
results were not affected by this choice.
To our knowledge this is one of the first studies
in which mp-MRI and biomarkers are compared in
RB candidates. Our results demonstrate that the
addition of mp-MRI to the base model produces the
highest AUC value (0.936) and that the perfor-
mance of the model is better than that of other
models, including base þ PCA3 and/or PHI models.
On multivariate analysis mp-MRI reached an OR of
99.521 (p <0.0001). In the full model mp-MRI alsoFigure 3. Net reduction in avoidable biopsies reported vs
various threshold probabilities (PCa prevalence of study 30.3%).
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with a considerable net reduction in avoidable bi-
opsies. In terms of the biomarkers, PCA3 appeared
to be an independent predictor only when mp-MRI
was not considered, yielding an OR of 3.878
(p ¼ 0.021) in the base þ PCA3 model, as happened
with PHI in the base þ PHI model (OR 3.517,
p ¼ 0.053). Although we put the imaging to the
same level of a PCa marker in this study, interest-
ingly mp-MRI performed better than the laboratory
tests in terms of the detection rate.
Our study is not free of limitations. The study
was limited by the relatively small number of cases
examined and further studies with a larger number
should be performed to confirm our findings.
Considering RB as reference standard could be a
limitation because the chance of missing tumors is
still present. Obviously the best reference is the
prostatectomy specimen, but this was not possible
in our setting. Moreover the inclusion of a single
expert uroradiologist who interpreted all of the
multiparametric MR images may affect the repro-
ducibility of our results in clinical practice. The re-
sults may actually underestimate the true
capabilities of mp-MRI at a center of excellence
using 3T machines and modern software, even if the
imaging protocol used satisfied the recommenda-
tions from a European consensus meeting.17 This
effect would be less if a standardized reporting
scheme is used like the PI-RADS classification,14,30but this prospective study started in 2011 when
the classification was not yet published. Finally, the
study does not include any discussion of costs and
logistics. Given the current health care crisis, these
issues are of key importance and further studies
should be advised.
Notwithstanding these limitations, we believe
that our results are noteworthy and could be
immediately transferable to the urological commu-
nity. Multiparametric MRI should be considered a
promising tool for avoiding unnecessary biopsies.
PCA3 and PHI do not appear to add further infor-
mation in a clinical setting with availability and
expertise in mp-MRI, suggesting a possible limita-
tion of their widespread use in this clinical scenario.
In light of these results we can imagine that the
future of PCa diagnosis in the RB setting is closely
related to mp-MRI.CONCLUSIONS
Our results indicate that mp-MRI has a high diag-
nostic accuracy in identifying patients with prostate
cancer in the RB setting compared with PCA3 and
PHI. Therefore, mp-MRI should be considered a
valid tool for avoiding unnecessary biopsies in pa-
tients with an initial negative PB and persistent
suspicion of PCa. If these data are confirmed by
other studies, the additional value of biomarkers
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